Stocks
Exelixis, Inc.EXEL
NASDAQHealthcareBiotechnology$41.24+0.17%
Focused on oncology drug development, this biotechnology company develops and commercializes targeted cancer therapies, with its lead product cabozantinib marketed as Cabometyx for several forms of advanced kidney and liver cancer. Revenue is largely driven by this franchise alongside collaboration ...
Market Cap: $11.1B52W Range: $32.38 – $49.62
Congressional Interest in Exelixis, Inc. (EXEL)
9 members of Congress have disclosed 13 trades in Exelixis, Inc. (EXEL), a Healthcare company. The buy/sell breakdown shows 6 purchases versus 7 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
13
Unique Politicians
9
Buys
6
Sells
7
Who in Congress Is Trading EXEL?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2020-08-04 | Joseph P. Kennedy | sell | $15K – $50K |
| 2020-06-05 | Kurt Schrader | sell | $15K – $50K |